Tags : Genetic diseases

M&A

 Roche to Acquire Spark Therapeutics for $4.3B

Shots: Roche acquires Spark Therapeutics, in all stock transaction for $114.50 /share in cash, making the total deal value $4.3B. Spark to receive premium of 122% based on its last day closing share price value i.e 22 February 2019 The focus of the acquisition is to expand Roche’s footprints in genetic disorders including blindness, hemophilia, […]Read More